Skip to content
#protein folding Review Open access

Organelle network dysfunction in primary cardiomyopathy: An integrated perspective on pathogenesis and therapeutics

Aug 2026 · Journal of Molecular and Cellular Cardiology Plus · Vol 17 · 0 citations · 148 references
Medicine

TL;DR

Treating primary cardiomyopathy as a 'organelle network disease', in which organelles constitute a dynamic, interdependent ecosystem, provides a useful integrative paradigm for comprehending the causes.

Abstract

Primary (genetic) cardiomyopathy comprises a heterogeneous group of predominantly monogenic (genetically determined) myocardial diseases—principally hypertrophic (HCM), dilated (DCM) and restrictive (RCM) phenotypes—and must be distinguished from secondary/acquired cardiomyopathies attributable to ischaemia, valvular disease, pressure overload, diabetes, infection or toxins. This review is restricted to primary cardiomyopathy; because organelle biology has been characterised far more extensively in secondary or acquired settings, evidence derived from such models (ischaemia–reperfusion, pressure overload, diabetes, sepsis, drug toxicity, neurodegenerative or non-cardiac injury models) is explicitly identified as such and treated as indirect, hypothesis-generating support rather than as direct evidence in primary cardiomyopathy. The pathophysiology of primary cardiomyopathy is tightly related to abnormal energy metabolism, protein homeostasis and calcium homeostasis. An increasing body of evidence suggests that organelle malfunction and abnormal inter-organelle interactions play a role in primary cardiomyopathy development. This review focuses on key organelles: mitochondrial dysfunction results in energy deprivation and oxidative imbalance; endoplasmic reticulum stress (ERS) impairs protein folding and calcium homeostasis; defects in the lysosome-mediated autophagy pathway exacerbate the accumulation of intracellular damaged material; Golgi fragmentation affects protein processing and trafficking; and cytoskeletal disruption compromises the structural integrity of myocardium. Furthermore, organelles create complex regulatory networks via structures like mitochondrial-associated ER membranes (MAMs), where imbalances such as aberrant calcium signalling and stress pathway cross-activation exacerbate pathological damage. While previous studies focus on individual proteins or organelles, the heart's high energy consumption and synchronized contraction require understanding cardiomyocytes as a dynamic, interdependent organelle ecosystem. Treating primary cardiomyopathy as a ‘organelle network disease’, in which organelles constitute a dynamic, interdependent ecosystem, provides a useful integrative paradigm for comprehending the causes. This review lays the groundwork for targeted therapy in primary cardiomyopathy by clarifying the functions of organelles.

Read PDF

Similar papers

Review Open access Aug 2026

Pediatric dilated cardiomyopathy and the progression to heart failure: mechanisms and interventions focusing on the “gene-inflammation-metabolism” axis

A pediatric-specific triaxial framework is presented that unifies known DCM pathways into a single actionable model for precision risk stratification and targeted therapy, and supports the development of novel biomarkers, multi-dimensional risk stratification strategies, and targeted interventions.

Jin-Song Jiang, D. Luo, Yan Gu et al. · 0 citations
Review Jul 2026

Targeted Therapies in Hypertrophic Cardiomyopathy: A Practical Review of Evidence, Implementation, and Innovation.

Hypertrophic cardiomyopathy (HCM) is a common inherited disorder characterized by sarcomere dysfunction leading to myocardial hypertrophy, diastolic impairment, and, in many patients can result in dynamic left ventricular outflow tract obstruction (LVOTO). Traditional pharmacologic management of HCM has relied on β-blo...

Madeline Smoot, James P. MacNamara, Michael P Ayers · 0 citations
Review Open access Jul 2026

Chronic Kidney Disease-Associated Cardiomyopathy: Mechanisms and Therapeutic Strategies.

A better understanding of CKD-CM pathogenesis is likely to enable early intervention and prevention, with successful outcomes measured by reduced progression to severe cardiomyopathy and lower cardiovascular mortality in CKD.

Konstantinos Grigoriou, Vasileios Lamprou, Anastasios Chatzichidiroglou et al. · 0 citations
Review Open access Aug 2026

ALS: An Organism-Wide Bioenergetic Failure Due to Mitochondrial Dysfunctions?

Targeting upstream mechanisms of mitochondrial impairment may provide a unifying strategy for understanding ALS pathogenesis and developing effective therapies.

Hiroshi Mitsumoto, H. Blasco, P. Corcia et al. · 0 citations
Open access Aug 2026

Acox2 deficiency induces cardiac dysfunction via cross-organ metabolic reprogramming in mice

Secondary cardiomyopathies are a major cause of heart failure (HF) with diverse etiologies and high mortality rates. For example, over 50% of patients with end-stage liver disease develop cardiac dysfunction, clinically termed cirrhotic cardiomyopathy (CCM). While serum metabolites mediating cross-organ communica...

Cancan Yao, Yan Chen, Zhouping Lu et al. · 0 citations

Related blog posts

Google DeepMind Blog Sep 30, 2026

Introducing SynthID Bio

Proof of concept for watermarking AI-generated proteins while preserving biological function.

MIT News · Artificial Intelligence Aug 27, 2026

Looking beyond natural sequences

A new machine-learning framework aims to improve the success rate of computational protein design while moving away from results that reproduce sequences found in nature.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.